News & Events
-
March 5, 2012
Could Genetics Improve Warfarin Dosing?
In a large-scale study and an upcoming clinical trial, scientists supported by the National Institutes of Health address one of the trickiest issues in prescribing medicine—how to quickly optimize each patient’s dosage of the common blood-thinning drug warfarin.... -
February 1, 2012
Critical Path Institute Announces New CEO
Critical Path Institute (C-Path) announced today that Dr. Carolyn Compton has joined the organization as its new president and chief executive officer. Dr. Compton takes over for Dr. Raymond L. Woosley, C-Path’s founder, who last year announced his intention to step down as President/CEO, and asked the Board of Directors to begin a search for...... -
January 23, 2012
European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials
Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has issued a positive opinion on the use of magnetic resonance imaging (MRI) to measure hippocampal volume as a tool to enrich recruitment into regulated clinical...... - December 23, 2011
-
December 20, 2011
Critical Path Institute and Hamner Institutes for Health Sciences Announce Collaboration to Improve Safety of Medical Product Development
Critical Path Institute(C-Path)and The Hamner Institutes for Health Sciences (The Hamner) announced today that they have signed a Memorandum of Understanding (MOU) to develop innovative, collaborative activities in the areas of regulatory science research for predicting, detecting and monitoring liver safety issues during the development of new medicines....